Stockscreener 앱 받기
21.98
5.07%
1.06
시간 외 거래:
21.98
전일 마감가:
$20.92
열려 있는:
$20.69
하루 거래량:
599.93K
Relative Volume:
0.77
시가총액:
$2.47B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-10.22
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
-0.18%
1개월 성능:
+18.88%
6개월 성능:
-6.67%
1년 성능:
+16.85%
1일 변동 폭
$20.53
$22.10
1주일 범위
$20.53
$22.75
52주 변동 폭
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
21.98 | 2.47B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target - MarketScreener
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating By Investing.com - Investing.com Nigeria
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating - Investing.com
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $42.89 Consensus Price Target from Analysts - Defense World
Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts strong analyst attentionWatchlist Winner Update - Newser
Why NewAmsterdam Pharma Company N.V. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
What makes NewAmsterdam Pharma Company N.V. stock price move sharplyFree Stock Market Insider Analysis - Newser
How NewAmsterdam Pharma Company N.V. stock performs during market volatilityFree Stock Market Knowledge Sharing - Newser
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyAlpha Stock Ideas - Newser
NewAmsterdam Pharma updates employment agreement with chief scientific officer By Investing.com - Investing.com India
NewAmsterdam Pharma updates employment agreement with chief scientific officer - Investing.com
Mirae Asset Global Investments Co. Ltd. Purchases 596 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by Wall Street Zen - Defense World
Thursday’s Insider Moves: Big Buys at NewAmsterdam Pharma, CME Group By Investing.com - Investing.com Nigeria
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup - Defense World
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Nigeria
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug By Investing.com - Investing.com South Africa
Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus
How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com
Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com India
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India
NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com
California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel - Insider Monkey
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Frazier Lifesciences Acquisition : NewAmsterdam Pharma R&D Day 2025 - MarketScreener
NewAmsterdam Pharma Schedules R&D Day for June 2025 - TipRanks
Brokers Set Expectations for NAMS FY2026 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus - Defense World
Kalkine: NewAmsterdam Pharma Progress in Nasdaq Index Spotlight Event - Kalkine Media
(NAMSW) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma (NAMS): Stifel Initiates Coverage with Buy Rating | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14% - simplywall.st
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14% - Yahoo Finance
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.37%
자본화:
|
볼륨(24시간):